Winship Cancer Institute
Emory University
Atlanta, GA
Filters
Save & Share
Clear Filters
Diagnosis
Risk Level
If known, please select your risk level (IPSS-R / IPSS-M).
MDS Centers of Excellence
Accepting patients
Orca-T
A Randomized Phase III Trial of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation With Either Orca-T, a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells, or Standard-of-Care Allogeneic Graft
Learn more- Allogeneic Stem Cell Transplant
- T Cell (Allogeneic)
- Phase 3
- Has results
Accepting patients
TakeAim
TakeAim Leukemia: A Phase 1/2A, Open Label Dose Escalation and Expansion Study of Orally Administered CA-4948 as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome and in Combination With Azacitidine or Venetoclax
Learn more- BCL-2 Inhibitor
- Hypomethylating Agents (HMA)
- IRAK 4 Inhibitor
- Phase 1/2
- Has results
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trialsAccepting patients
A Phase 1b/2 Study Evaluating the Safety and Efficacy of Canakinumab With Darbepoetin Alfa in Patients With Lower-Risk Myelodysplastic Syndromes (MDS) Who Have Failed Erythropoietin Stimulating Agents (ESA)
Learn more- Erythropoiesis-Stimulating Agent (ESA)
- Monoclonal Antibody
- Red Blood Cell Stimulant
- Phase 1/2
- Has results
Accepting patients
SX-682
A Phase 1, Open-Label, Dose-Escalation With Expansion Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
Learn more- CXCR1 Inhinitor
- CXCR2 Inhinitor
- Phase 1
- Has results
Accepting patients
SAR443579
An Open-label, First-in-human, Dose-escalation/Expansion Study of SAR443579 Administered as Single Agent by Intravenous Infusion in Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS)
Learn more- Trispecific NK Engager
- Phase 1/2
- Has results
Accepting patients
Orca-T
A Multicenter Phase Ib Trial of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation With Orca-T (Formerly TregGraft), a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells
Learn more- T Cell (Allogeneic)
- Phase 1
- Has results
Accepting patients
CLN-049
A Phase 1, Open-label, Preliminary Pharmacokinetics (PK) and Safety Study of CLN-049 (An Fms-like Tyrosine Kinase 3 [FLT3] x Cluster of Differentiation 3 [CD3] Bispecific T Cell Engager) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Learn more- FLT3
- Tyrosine Kinase (TK) Inhibitor
- Phase 1
Accepting patients
Vorinostat for GVHD Prevention
A Phase 1/2 Multi-Center Trial of Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
Learn more- Allogeneic Stem Cell Transplant
- HDAC Inhibitor
- Phase 1/2
Accepting patients
LIMBER
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
Learn more- BET Inhibitor
- JAK1 Inhibitor
- JAK2 Inhibitor
- Phase 1
Accepting patients
A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignancies With Isocitrate Dehydrogenase (IDH) Mutations
Learn more- MIDH2 Inhibitor
- MIDH1 Inhibitor
- Phase 1
Filters
Save & Share
Diagnosis
Risk Level
If known, please select your risk level (IPSS-R / IPSS-M).
MDS Centers of Excellence
Advanced Filters
Hide Trials
These are additional options that allow you to hide (or filter out) trial options that may not be right for you.
Trial Enrollment Status
Treatment Classifications
Filter results based on treatment classifications/type.
Trial Type
Phase
MDS Classification
Has your MDS been classified as primary (cause unknown) or secondary (treatment related)?